Catalio Capital Management, in its April letter seen by Hedge Fund Alpha, shared a shift in the performance of its public equity fund. While as of April, the fund delivered -6.49% YTD gains, April seems to be the turning point. In the last month, the fund generated 6.41% returns, bringing their YTD gains to -0.50%. Amid rough markets for biotech, the hedge fund has returned 33% since inception versus a return of -27% for XBI (SPDR S&P Biotech ETF)
Read more hedge fund letters here
Catalio Capital Management was founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein with the aim of investing in the next generation of life science companies worldwide. Catalio Capital manages a...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
